Patients on the checkpoint inhibitor nivolumab who present with symptoms of colitis should be investigated to exclude other causes, including infections such as cytomegalovirus, a drug safety update advises. A Europe wide review identified 20 serious cases suggestive of cytomegalovirus (CMV) infection or reactivation with nivolumab monotherapy. A further 8 cases were reported of either ...
Vigilance for CMV urged with nivolumab
7 Nov 2019